Insecticides (India) Limited has informed the Exchange about Transcript
INSECTICID · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Insecticides (India) reported Q1 FY26 revenue of INR691 cr, up 5% YoY, driven by strong premium product growth. EBITDA rose to INR85 cr with margin expanding ~122 bps to 12%, and PAT grew 18% YoY to INR58 cr. The B2C mix stands at 75% of sales, with premium products now forming 58% of B2C revenue and growing 20% in the quarter. Twelve new products launched last year contributed INR42 cr in Q1 alone, versus INR34 cr for the entire previous year. Management has completed the Dahej technical plant capex and is now building the Sotanala facility (formulation by next kharif, technical by FY27 end).
The margin expansion guidance of ~100 bps annually over 2-3 years, combined with strong premium product traction and completed Dahej capex, signals improving profitability trajectory. However, near-term Q2 may be flat-to-marginally-up vs Q1 due to expected sales returns, which could temper immediate stock sentiment despite the positive structural story.